139 related articles for article (PubMed ID: 37985171)
41. CD69 expression potentially predicts response to bendamustine and its modulation by ibrutinib or idelalisib enhances cytotoxic effect in chronic lymphocytic leukemia.
Montraveta A; Lee-Vergés E; Roldán J; Jiménez L; Cabezas S; Clot G; Pinyol M; Xargay-Torrent S; Rosich L; Arimany-Nardí C; Aymerich M; Villamor N; López-Guillermo A; Pérez-Galán P; Roué G; Pastor-Anglada M; Campo E; López-Guerra M; Colomer D
Oncotarget; 2016 Feb; 7(5):5507-20. PubMed ID: 26701728
[TBL] [Abstract][Full Text] [Related]
42. Hemophagocytic Lymphohistiocytosis With Cerebral Involvement in Richter's Syndrome.
Joris M; Guiheneuf E; Rumebe L; Claisse JF; Gruson B; Royer B
J Clin Oncol; 2016 Jun; 34(16):e148-50. PubMed ID: 25534389
[No Abstract] [Full Text] [Related]
43. Chronic Myelogenous Leukemia Diagnosed in the Setting of Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Viswanathan K; Roboz G; Chadburn A; Mathew S
Int J Surg Pathol; 2020 Apr; 28(2):216-224. PubMed ID: 31544558
[TBL] [Abstract][Full Text] [Related]
44. Random Skin Biopsy Is a Useful Procedure in the Evaluation of Hemophagocytic Lymphohistiocytosis: A Case Report and Review of Literature.
Hegazy S; Moesch J; Guerrero A; Ho J; Karunamurthy A
Am J Dermatopathol; 2022 Dec; 44(12):925-928. PubMed ID: 36197063
[TBL] [Abstract][Full Text] [Related]
45. Hemophagocytic Lymphohistiocytosis in Renal Transplant Recipients: A 2-Case Report.
Mascia G; Argiolas D; Carta E; Ibba S; Piredda GB
Transplant Proc; 2020 Jun; 52(5):1566-1569. PubMed ID: 32389490
[TBL] [Abstract][Full Text] [Related]
46. Safety and Efficacy of Bendamustine Monotherapy in the First-Line Treatment of Patients with Chronic Lymphocytic Leukemia: Polish Lymphoma Research Group Real-Life Analysis.
Wołowiec D; Szymczyk A; Potoczek S; Krochmalczyk D; Zawirska D; Piotrowska M; Malenda A; Soroka-Wojtaszko M; Kopacz A; Wąsik-Szczepanek E; Graboś-Michalak J; Raźny M; Wichary R; Bramowicz-Jarosz B; Seweryn M; Długosz-Danecka M; Hus I
Chemotherapy; 2019; 64(3):155-162. PubMed ID: 31715597
[TBL] [Abstract][Full Text] [Related]
47. Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study.
Cuneo A; Mato AR; Rigolin GM; Piciocchi A; Gentile M; Laurenti L; Allan JN; Pagel JM; Brander DM; Hill BT; Winter A; Lamanna N; Tam CS; Jacobs R; Lansigan F; Barr PM; Shadman M; Skarbnik AP; Pu JJ; Sehgal AR; Schuster SJ; Shah NN; Ujjani CS; Roeker L; Orlandi EM; Billio A; Trentin L; Spacek M; Marchetti M; Tedeschi A; Ilariucci F; Gaidano G; Doubek M; Farina L; Molica S; Di Raimondo F; Coscia M; Mauro FR; de la Serna J; Medina Perez A; Ferrarini I; Cimino G; Cavallari M; Cucci R; Vignetti M; Foà R; Ghia P;
Cancer Med; 2020 Nov; 9(22):8468-8479. PubMed ID: 32969597
[TBL] [Abstract][Full Text] [Related]
48. Contribution of clonal hematopoiesis to adult-onset hemophagocytic lymphohistiocytosis.
Miller PG; Sperling AS; Gibson CJ; Viswanathan K; Castellano C; McConkey M; Ceremsak J; Taylor MS; Birndt S; Perner F; Arnason J; Agrawal M; Schram AM; Nikiforow S; Pihan G; Hasserjian RP; Aster JC; La Rosée P; Morgan EA; Berliner N; Ebert BL
Blood; 2020 Dec; 136(26):3051-3055. PubMed ID: 32961550
[TBL] [Abstract][Full Text] [Related]
49. Bendamustine hydrochloride in patients with B-cell malignancies who have comorbidities - is there an optimal dose?
Gordon MJ; Lewis LD; Brown JR; Danilov AV
Expert Rev Hematol; 2017 Aug; 10(8):707-718. PubMed ID: 28664772
[TBL] [Abstract][Full Text] [Related]
50. Monoclonal B-cell lymphocytosis in the bone marrow: revisiting the criteria for chronic lymphocytic leukemia/small lymphocytic lymphoma.
Ryder CB; Oduro KA; Moore EM
Hum Pathol; 2022 Jul; 125():108-116. PubMed ID: 35472399
[TBL] [Abstract][Full Text] [Related]
51. [Efficacy and safety of BTK inhibitor combined with bendamustine and rituximab in the first-line treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma].
Qin SC; Jiang R; Sha YQ; Qiu JY; Mi HL; Miao Y; Wu W; Wang L; Fan L; Xu W; Li JY; Zhu HY
Zhonghua Xue Ye Xue Za Zhi; 2023 Feb; 44(2):158-161. PubMed ID: 36948873
[No Abstract] [Full Text] [Related]
52. Efficacy and Safety of Bendamustine and Ibrutinib in Previously Untreated Patients With Chronic Lymphocytic Leukemia: Indirect Comparison.
Andrasiak I; Rybka J; Knopinska-Posluszny W; Wrobel T
Clin Lymphoma Myeloma Leuk; 2017 May; 17(5):268-273. PubMed ID: 28395851
[TBL] [Abstract][Full Text] [Related]
53. Obinutuzumab plus bendamustine for relapsed/refractory chronic lymphocytic leukemia and predictive and prognostic impact of genetic alterations: the phase II GABRIELL study.
Bravo J; Baltasar Tello P; González Garcia E; Ríos Herranz E; Páyer AR; Terol Castera MJ; Champ D; Medina Perez A; Gironella M; Fernández Zarzoso M; Forés R; Delgado J; Garcia-Marco JA;
Leuk Lymphoma; 2023 May; 64(5):913-926. PubMed ID: 37255002
[TBL] [Abstract][Full Text] [Related]
54. Combination trial of duvelisib (IPI-145) with rituximab or bendamustine/rituximab in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia.
Flinn IW; Cherry MA; Maris MB; Matous JV; Berdeja JG; Patel M
Am J Hematol; 2019 Dec; 94(12):1325-1334. PubMed ID: 31490009
[TBL] [Abstract][Full Text] [Related]
55. Idelalisib and bendamustine combination is synergistic and increases DNA damage response in chronic lymphocytic leukemia cells.
Modi P; Balakrishnan K; Yang Q; Wierda WG; Keating MJ; Gandhi V
Oncotarget; 2017 Mar; 8(10):16259-16274. PubMed ID: 28187444
[TBL] [Abstract][Full Text] [Related]
56. Hemophagocytic histiocytosis in severe SARS-CoV-2 infection: A bone marrow study.
Dandu H; Yadav G; Malhotra HS; Pandey S; Sachu R; Dubey K
Int J Lab Hematol; 2021 Dec; 43(6):1291-1301. PubMed ID: 34086418
[TBL] [Abstract][Full Text] [Related]
57. Retreatment with bendamustine-containing regimens in patients with relapsed/refractory chronic lymphocytic leukemia and indolent B-cell lymphomas achieves high response rates and some long lasting remissions.
Weide R; Feiten S; Friesenhahn V; Heymanns J; Kleboth K; Thomalla J; van Roye C; Köppler H
Leuk Lymphoma; 2013 Aug; 54(8):1640-6. PubMed ID: 23151046
[TBL] [Abstract][Full Text] [Related]
58. Bendamustine for the treatment of indolent non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
Elefante A; Czuczman MS
Am J Health Syst Pharm; 2010 May; 67(9):713-23. PubMed ID: 20410545
[TBL] [Abstract][Full Text] [Related]
59. Akt inhibitor MK-2206 in combination with bendamustine and rituximab in relapsed or refractory chronic lymphocytic leukemia: Results from the N1087 alliance study.
Larsen JT; Shanafelt TD; Leis JF; LaPlant B; Call T; Pettinger A; Hanson C; Erlichman C; Habermann TM; Reeder C; Nikcevich D; Bowen D; Conte M; Boysen J; Secreto C; Lesnick C; Tschumper R; Jelinek D; Kay NE; Ding W
Am J Hematol; 2017 Aug; 92(8):759-763. PubMed ID: 28402581
[TBL] [Abstract][Full Text] [Related]
60. A canadian perspective on the first-line treatment of chronic lymphocytic leukemia.
Owen C; Bence-Bruckler I; Chamakhi I; Toze C; Assaily W; Christofides A; Robinson S
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):303-13. PubMed ID: 25937158
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
